ArticleNature2024
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Progress in epigenetic research of breast cancer: a bibliometric analysis since the 2000s.Frontiers in oncology · 2025Pooled it
- Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.Molecular cancer therapeutics · 2026Article
- Structural characteristics and SARs of EZH2 inhibitors.Molecular diversity · 2026Review
- Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer.Acta pharmacologica Sinica · 2026Review
- Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities.Biomedicines · 2026Review
- Ultrasound-activated RuORSC advances · 2026Article
- The role of artificial intelligence in precision medicine for breast cancer.Discover oncology · 2026Review
- A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026Review
- Discovery of a potent and orally bioavailable type Ⅰ PRMTs inhibitor for triple-negative breast cancer treatment.Acta pharmacologica Sinica · 2026Article
- Review
- EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity.EMBO reports · 2026Article
- Biomimetic nanovesicle with tri-pronged immune amplification for efficient photo-immunotherapy against triple-negative breast cancer.Materials today. Bio · 2026Article
- Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase.Cancer discovery · 2026Article
- Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAFOncology research · 2026Article
- Overcoming Therapeutic Resistance in Triple-Negative Breast Cancer: Targeting the Undrugged Kinome.International journal of molecular sciences · 2025Review
- Review
- Iron-doped Zif-8 nanoplatform for MRI-guided synergistic microwave thermal/chemodynamic therapy of triple-negative breast cancer.International journal of pharmaceutics: X · 2025Article
- RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.Cell death & disease · 2025Article
- Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis.Scientific reports · 2025Article
- Lon peptidase 1 promotes proliferation and metastasis in breast cancer via interleukin 6 signaling.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Amy E SchadeDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Naiara PerurenaDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-0874-3389
Yoona YangCedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.ORCID 0000-0002-7446-8816
Carrie L RodriguezDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-6796-8054
Anjana KrishnanDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Alycia GardnerDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-2185-5174
Patrick LoiDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0001-8476-3803
Yilin XuLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0009-0002-5696-7475
Van T M NguyenDivision of Cancer Biology, Institute of Cancer Research, London, UK.
G M MastelloneDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Natalie F PillaDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-9971-3590
Marina WatanabeDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Keiichi OtaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rachel A DavisDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Kaia MattioliDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Dongxi XiangDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
Jason J ZoellerLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3531-2111
Jia-Ren LinLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4702-7705
Stefania MorgantiDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5284-9944
Ana C Garrido-CastroDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5989-6636
Sara M TolaneyDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5940-8671
Zhe LiDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Peter K SorgerLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3364-1838
Kristian HelinDivision of Cancer Biology, Institute of Cancer Research, London, UK.ORCID 0000-0003-1975-6097
Sandro SantagataLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7528-9668
Simon R V KnottCedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.
Karen CichowskiDivision of Genetics, Brigham and Women's Hospital, Boston, MA, USA. kcichowski@rics.bwh.harvard.edu.ORCID 0000-0003-3940-3782
Funding
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2018 to 2022
$10.8MInterplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant fieldR01CA222560 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI LI, ZHE · 2018 to 2022
$1.9MAdvancing technologies for the collection and analysis of high dimensional immunoprofiles and tumor imagesR50CA274277 · NCI · HARVARD MEDICAL SCHOOL · PI Jia-Ren Lin · 2022 to 2026
$879kTargeting the Epigenome to Improve Responses to ImmunotherapyK00CA245807 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GARDNER, ALYCIA · 2022 to 2025
$404kDecoding the role of transcription factor isoformsF32HG012318 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI MATTIOLI, KAIA · 2022 to 2023
$109kNCI NIH HHS K00 CA245807NCI NIH HHS R01 CA222560NCI NIH HHS R50 CA274277NCI NIH HHS U54 CA225088NHGRI NIH HHS F32 HG012318
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence
Indexed as
Antineoplastic AgentsEnhancer of Zeste Homolog 2 ProteinProtein Kinase InhibitorsProto-Oncogene Proteins c-aktTriple Negative Breast NeoplasmsAnimalsCell DeathCell DifferentiationCell Line, TumorDrug SynergismDrug Therapy, CombinationFemaleHumansMachine LearningMiceOrgan SpecificityAntineoplastic AgentsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-akt
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.